Publications
Research at the Leibniz Institute for Immunology focuses on the development of pioneering immune-cell therapies targeting cancer, autoimmune diseases, and chronic inflammation. While developments in this field are highly relevant within the medical community, they are also of great interest to the wider general public. The LIT has a comprehensive archive of international articles, publications, lectures, and online resources aimed at a variety of audiences. So, whoever you are, if you do not find what you are looking for, please do not hesitate to contact us.
Galletti G, De Simone G, Mazza EMC, Puccio S, Mezzanotte C, Bi TM, Davydov AN, Metsger M, Scamardella E, Alvisi G, De Paoli F, Zanon V, Scarpa A, Camisa B, Colombo FS, Anselmo A, Peano C, Polletti S, Mavilio D, Gattinoni L, Boi SK, Youngblood BA, Jones RE, Baird DM, Gostick E et al. Two subsets of stem-like CD8(+) memory T cell progenitors with distinct fate commitments in humans. Nat Immunol. 2020 Dec. 21:1552-1562. doi:10.1038/s41590-020-0791-5. PMID: 33046887
Denk A, Mittermaier C, Weber D, Fante M, Gunes S, Edinger M, Herr W, Wolff D. Efficacy and safety of ruxolitinib in the treatment of chronic graft-versus-host disease: a retrospective analysis. Ann Hematol. 2024 Sep. 103:3755-3764. doi:10.1007/s00277-024-05697-w. PMID: 38916742
Schelker RC, Fioravanti J, Mastrogiovanni F, Baldwin JG, Rana N, Li P, Chen P, Vadász T, Spolski R, Heuser-Loy C, Slavkovic-Lukic D, Noronha P, Damiano G, Raccosta L, Maggioni D, Pullugula S, Lin JX, Oh J, Grandinetti P, Lecce M, Hesse L, Kocks E, Martín-Santos A, Gebhard C, Telford WG, Ji Y, Restifo NP, Russo V, Rehli M, Herr W, Leonard WJ, Gattinoni L. LIM-domain-only 4 (LMO4) enhances CD8+ T-cell stemness and tumor rejection by boosting IL-21-STAT3 signaling. Signal Transduct Target Ther. 2024 Aug 9;9(1):199. doi: 10.1038/s41392-024-01915-z. PMID: 39117617
Fischer-Riepe L, Kailayangiri S, Zimmermann K, Pfeifer R, Aigner M, Altvater B, Kretschmann S, Volkl S, Hartley J, Dreger C, Petry K, Bosio A, von Dollen A, Hartmann W, Lode H, Gorlich D, Mackensen A, Jungblut M, Schambach A, Abken H, Rossig C. Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers. Clin Cancer Res. 2024 Aug 15. 30:3564-3577. doi:10.1158/1078-0432.CCR-23-3157. PMID: 38593230
Denk A, Edinger M, Weber D, Holler E, Fante M, Meedt E, Gunes S, Poeck H, Mittermaier C, Herr W, Wolff D. Ruxolitinib for the treatment of acute graft-versus-host disease: a retrospective analysis. Ann Hematol. 2024 Aug. 103:3071-3081. doi:10.1007/s00277-024-05696-x. PMID: 38916740
Abken H. Transforming the Dark into Light: A Siglec-9 Switch. Cancer Immunol Res. 2024 Jul 22.OF1. doi:10.1158/2326-6066.CIR-24-0429. PMID: 39037058
Mirus T, Lohmayer R, Döhring C, Halldórsson BV, Kehr B. GGTyper: genotyping complex structural variants using short-read sequencing data. Bioinformatics 2024.
Heudobler D, Luke F, Hahn J, Grube M, Schlosser P, Kremers S, Sudhoff T, Westermann J, Hutter-Kronke ML, Schlenk RF, Weber D, Paschka P, Zeman F, Dohner H, Herr W, Reichle A*, Thomas S*. Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged ≥ 60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): results of the safety run-in phase. Haematologica 2024; 109(4):1274. doi: 10.3324/haematol.2023.283864. PMID: 37881883. *shared authorship
Hammon K, Renner K, Althammer M, Voll F, Babl N, Decking SM, Siska PJ, Matos C, Conejo ZEC, Mendes K, Einwag F, Siegmund H, Iberl S, Berger RS, Dettmer K, Schoenmehl R, Brochhausen C, Herr W, Oefner PJ, Rehli M, Thomas S*, Kreutz M*. D-2-hydroxyglutarate supports a tolerogenic phenotype with lowered major histocompatibility class II expression in non-malignant dendritic cells and acute myeloid leukemia cells. Haematologica. 2024 Jan 18. doi: 10.3324/haematol.2023.283597. PMID: 38235501. Online ahead of print. *shared authorship
Feldker N, Ferrazzi F, Schuhwerk H, Widholz SA, Guenther K, Frisch I, Jakob K, Kleemann J, Riegel D, Bonisch U, Lukassen S, Eccles RL, Schmidl C, Stemmler MP, Brabletz T, Brabletz S. Genome-wide cooperation of EMT transcription factor ZEB1 with YAP and AP-1 in breast cancer. EMBO J. 2020 Sep 1. 39:e103209. doi:10.15252/embj.2019103209. PMID: 32692442